Alterity Therapeutics Reports Progress Amid Financial Losses

Alterity Therapeutics Ltd. ( (PRNAF) ) has released its Q2 earnings. Here is a breakdown of the information Alterity Therapeutics Ltd. presented to its investors.

Alterity Therapeutics Ltd., formerly known as Prana Biotechnology Ltd., is a biotechnology company focused on developing treatments for neurodegenerative diseases, particularly Multiple System Atrophy (MSA) and Parkinson’s disease. In its latest earnings report for the half-year ended December 31, 2024, Alterity Therapeutics highlighted significant progress in its clinical development programs, despite reporting a net loss of A$7.17 million, up 10.2% from the previous year. The company’s revenue from ordinary activities decreased by 6% to A$111,299, primarily from interest income. Alterity achieved notable milestones in its research, including positive results from its ATH434-201 Phase 2 clinical trial for MSA, which demonstrated a 48% slowing of clinical progression at the 50 mg dose. The company also raised approximately A$42 million to support further development of ATH434 and other research initiatives. Looking ahead, Alterity’s management remains optimistic about advancing its clinical pipeline and achieving regulatory milestones, aiming to develop the first disease-modifying treatment for neurodegenerative diseases.